Neuropace, Inc. - Common Stock (NPCE)

7.5600
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 16th, 5:48 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close7.560
Open-
Bid7.040
Ask7.480
Day's RangeN/A - N/A
52 Week Range5.460 - 19.60
Volume5,655
Market Cap183.68M
PE Ratio (TTM)-21.00
EPS (TTM)-0.4
Dividend & YieldN/A (N/A)
1 Month Average Volume411,847

Chart

About Neuropace, Inc. - Common Stock (NPCE)

NeuroPace Inc is a medical technology company that specializes in developing innovative neuromodulation devices aimed at transforming the treatment of neurological disorders. The company's flagship product is an implantable brain device that delivers responsive neurostimulation to manage epilepsy, helping patients who do not achieve adequate control with traditional medication. By continuously monitoring brain activity, NeuroPace's technology can provide targeted therapy in real-time, resulting in improved quality of life for individuals suffering from chronic seizures. Committed to advancing research and patient care, NeuroPace is at the forefront of personalized medicine in the neurological field. Read More

News & Press Releases

Today's US Session Top Gainers and Losers: ONFO, AKAN Lead Advances; OPTT, NPCE Fallchartmill.com
Via Chartmill · November 13, 2026
Top US Market Movers: Gainers and Losers in Today's Sessionchartmill.com
Via Chartmill · November 13, 2026
Gap Movers for Nov. 13, 2026: Gap-Up and Gap-Down Stockschartmill.com
Via Chartmill · November 13, 2026
Premarket Session Market Movers: Small-Cap Gainers and Loserschartmill.com
Via Chartmill · November 13, 2026
NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidancechartmill.com
Via Chartmill · May 12, 2026
NeuroPace (NPCE) Q3 2026 Earnings Call Transcriptfool.com
Account issues and sales restructuring pressured results, prompting a guidance cut.
Via The Motley Fool · November 13, 2026
What NeuroPace (NPCE) Said on Its Q3 Earnings Callmarketbeat.com
NeuroPace (NASDAQ:NPCE) cut its full-year revenue outlook after third-quarter sales fell short of management’s expectations, as disruptions at major treatment centers and changes to its sales organization slowed procedures using its RNS System. The company reported third-quarter revenue of $23.1 mi
Via MarketBeat · November 12, 2026
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
By NeuroPace, Inc. · Via Business Wire · November 12, 2026
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
By NeuroPace, Inc. · Via Business Wire · October 29, 2026
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference.
By NeuroPace, Inc. · Via Business Wire · September 1, 2026
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
By NeuroPace, Inc. · Via Business Wire · August 31, 2026
NeuroPace Q2 Earnings Call Highlightsmarketbeat.com
NeuroPace (NASDAQ:NPCE) reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administrat
Via MarketBeat · August 11, 2026
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
By NeuroPace, Inc. · Via Business Wire · August 11, 2026
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Datamarketbeat.com
NeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant idiopathic generalized epilepsy, or IGE, was not approvable in its current form. The company said th
Via MarketBeat · July 28, 2026
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · July 28, 2026
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE).
By NeuroPace, Inc. · Via Business Wire · July 28, 2026
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical outcomes with the RNS® System, NAUTILUS results in idiopathic generalized epilepsy (IGE), and the continued evolution of data-driven tools that support treatment planning, patient management and practice development.
By NeuroPace, Inc. · Via Business Wire · May 29, 2026
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.
By NeuroPace, Inc. · Via Business Wire · May 29, 2026
NeuroPace (NPCE) Q1 2026 Earnings Transcriptfool.com
NeuroPace (NPCE) Q1 2026 Earnings Transcript
Via The Motley Fool · May 14, 2026
NeuroPace Q1 Earnings Call Highlightsmarketbeat.com
NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers. The company reported total revenue of $22.1 million for the first qu
Via MarketBeat · May 12, 2026
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
By NeuroPace, Inc. · Via Business Wire · May 12, 2026
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close on Tuesday, May 12, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
By NeuroPace, Inc. · Via Business Wire · April 29, 2026
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting.
By NeuroPace, Inc. · Via Business Wire · April 27, 2026
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference.
By NeuroPace, Inc. · Via Business Wire · April 10, 2026
NeuroPace to Present at the Leerink Global Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference.
By NeuroPace, Inc. · Via Business Wire · March 5, 2026